Khushi MT 200/200mg Kit 5s

Khushi MT 200/200mg Kit 5s is a combined treatment involving a progesterone receptor antagonist (Mifepristone) and a prostaglandin E1 analogue (Misoprostol). The two medications are used in a specific clinical sequence to achieve a medical abortion.

Mifepristone, the first medication in the regimen, binds to progesterone receptors in the uterine lining. By blocking progesterone, it causes the lining to break down and prevents the pregnancy from remaining attached to the uterine wall. It also increases the sensitivity of the uterine muscle to prostaglandins. Misoprostol, the second medication, is administered 24 to 48 hours later. It acts directly on the myometrium (uterine muscle) to induce contractions and causes cervical ripening. Together, these actions result in the evacuation of the uterus, a process that typically involves significant cramping and bleeding.

This regimen is intended for use under the supervision of a healthcare provider and requires a confirmed diagnosis of the duration of pregnancy, typically via ultrasound or clinical examination. It is not effective for ectopic pregnancies (pregnancies outside the uterus). Patients using this medication must have access to emergency medical care in the event of incomplete evacuation or excessive bleeding. A follow-up assessment is mandatory to ensure the procedure is complete and to monitor for any complications.

Khushi MT 200/200mg Kit 5s may be indicated by your doctor for:

Medical Termination of Pregnancy

To end an intrauterine pregnancy through the 10th week (70 days) of gestation.

Management of Early Pregnancy Loss

To assist in the completion of a miscarriage when the body does not expel the tissue naturally.

Khushi MT 200/200mg Kit 5s may provide benefits such as:

• Offers a non-surgical option for the termination of early pregnancy.

• Can be used in a private setting (for the second stage of the process) depending on local medical protocols.

• High success rate (approximately 95% to 98%) for completing medical abortion in the first trimester.

• Avoids the risks associated with general anaesthesia or invasive surgical instruments.

• Mimics the physiological process of a natural miscarriage.

Common side effects of Khushi MT 200/200mg Kit 5s may include:

• Heavy vaginal bleeding and passage of large blood clots

• Strong uterine cramping and pelvic pain

• Nausea and vomiting

• Diarrhoea

• Fever, chills, or shivering (usually shortly after taking Misoprostol)

• Dizziness and headache

Uncommon side effects of Khushi MT 200/200mg Kit 5s may include:

• Fatigue or general weakness

• Back pain

• Fainting

Serious side effects that may require immediate medical attention include:

• Haemorrhage: Bleeding so heavy that it soaks through two or more thick maxi pads per hour for two consecutive hours.

• Infection (Sepsis): Severe abdominal pain, feeling very ill, or a persistent fever (over 100.4°F or 38°C) lasting more than 4 hours.

• Incomplete Abortion: Persistent bleeding or cramping, which may indicate that some tissue remains in the uterus.

• Ectopic Pregnancy Rupture: Severe one-sided pelvic pain, which the medication cannot treat.

Always consult your doctor if you notice any persistent or concerning symptoms while using Khushi MT 200/200mg Kit 5s.

Use Khushi MT 200/200mg Kit 5s exactly as directed by your doctor based on the prescribed protocol. This is usually done in a clinical setting.

• Step 1: Swallow one (200 mg) mifepristone tablet orally.

• Step 2: After 24 to 48 hours, take 800 mcg of misoprostol (four 200 mcg tablets).

Buccal: Placing two tablets in each cheek pouch for 30 minutes.

Sublingual: Placing four tablets under the tongue for 30 minutes.

Vaginal: Inserting four tablets into the vagina.

• Step 3: A follow-up visit with a doctor (usually 7–14 days later) is critical to confirm with an ultrasound or blood test that the abortion is complete.

Khushi MT 200/200mg Kit 5s works through a two-step biological process.

Mifepristone is a progesterone receptor antagonist. Progesterone is essential for maintaining the uterine lining and supporting pregnancy. By blocking progesterone, mifepristone causes the uterine lining to break down, detaches the pregnancy tissue, and softens the cervix, preparing the uterus for expulsion.

Misoprostol, taken 24–48 hours later, is a prostaglandin E1 analogue. It induces cervical ripening and strong uterine contractions, which lead to the expulsion of pregnancy tissue.

Together, this combination mimics a natural miscarriage process. Mifepristone initiates pregnancy termination by removing hormonal support, while misoprostol completes the process by contracting the uterus. This sequential mechanism makes the regimen highly effective for medical termination of pregnancy up to 70 days (10 weeks) of gestation.

• Expect bleeding that is heavier than a normal period; have plenty of high-absorbency maxi pads ready.

• Ibuprofen is typically recommended for managing cramps; avoid Aspirin as it may increase bleeding unless told otherwise by your doctor.

• Do not use this medication if you have an Intrauterine Device (IUD) in place; it must be removed before treatment begins.

• You can become pregnant again very soon after this procedure; discuss contraception options with your doctor during your visit.

• If you have a negative blood type (Rh-negative), you may need an injection of Rh immune globulin to prevent future pregnancy complications.

• Store at room temperature in a cool, dry place.

• Protect from light and moisture.

• Keep the tablets in their original blister packaging until the time of use.

• Keep out of the reach of children and pets.

• Grapefruit Juice (SEVERE): Grapefruit can significantly increase the levels of Mifepristone in the blood, potentially increasing the risk of side effects.

• General Diet (NO INTERACTION): Most foods do not interfere with the treatment, though a light diet is recommended to manage nausea.

• Corticosteroids (MODERATE): Mifepristone blocks the effects of steroids like prednisone; doses may need adjustment for patients on long-term steroid therapy.

• CYP3A4 Inhibitors (CAUTION): Drugs like Ketoconazole or Erythromycin can increase the levels of Mifepristone.

• Anticonvulsants (CAUTION): Medicines like Phenytoin or Carbamazepine may decrease the effectiveness of the treatment.

• Ectopic Pregnancy (SEVERE): This medication will not work for a pregnancy outside the uterus and can not be suitable if one is present.

• Adrenal Failure (SEVERE): Mifepristone is contraindicated in patients with chronic adrenal failure.

• Bleeding Disorders (SEVERE): Should not be used by patients with porphyria or those on long-term blood thinners (anticoagulants).

• Severe Asthma (CAUTION): Use with care in patients with uncontrolled asthma, particularly if on steroid treatments.

In the event of taking more than the prescribed amount, or if severe symptoms occur, such as extremely heavy bleeding (soaking through more than two large pads per hour for two hours), severe abdominal pain, high fever, or fainting, immediate medical attention is required.

For assistance with a suspected overdose, contact a local poison control centre or seek emergency medical services at a hospital.

If a dose is missed or if the timing between the two medications does not follow the prescribed schedule, it is necessary to contact the prescribing healthcare provider or clinic immediately. They will provide instructions on how to proceed based on the specific circumstances.